Atrophy-related ubiquitin ligases atrogin-1 and MuRF-1 are associated with uterine smooth muscle involution in the postpartum period.

The regulation of cell size depends on a delicate balance between protein synthesis and breakdown. Skeletal and cardiac muscle adapt to hormonal and neuronal stimuli and can rapidly hypertrophy and atrophy; however, the extent to which these processes occur in smooth muscle is less clear. Atrophy in striated muscle results from enhanced protein breakdown and is associated with a common transcriptional profile and activation of the ubiquitin-proteasome pathway, including induction of the muscle-specific ubiquitin protein ligases atrogin-1 and muscle ring-finger protein 1 (MuRF-1). Here we show that atrogin-1 is also expressed in smooth muscle, and that both atrogin-1 and MuRF-1 are upregulated in the uterus following delivery, as rapid involution occurs. While these two genes are similarly induced in all types of muscle during rapid loss of cell mass, other striated muscle atrophy-specific transcriptional changes are not observed during uterine involution, suggesting different underlying molecular mechanisms. These results raise the possibility that activation of atrogin-1 and MuRF-1 may be a common general adaptation in cells undergoing a rapid reduction in size.

[1]  M. Devonald,et al.  Current opinion in clinical nutrition and metabolic care. , 2008, Current opinion in clinical nutrition and metabolic care.

[2]  A Celentano,et al.  Cardiac abnormalities in young women with anorexia nervosa. , 1994, British heart journal.

[3]  J. Papadimitriou,et al.  Regression of Left Ventricular Dilation and Hypertrophy after Removal of Volume Overload: Morphological and Ultrastructural Study , 1974, Circulation research.

[4]  U. Beller,et al.  Protease and protease inhibitory activity in pregnant and postpartum involuting uterus. , 1982, American journal of obstetrics and gynecology.

[5]  G. Yancopoulos,et al.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.

[6]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Riggs,et al.  Genomic Sequencing , 2010 .

[8]  C. Morton,et al.  Genetics of uterine leiomyomata , 2000, Bulletin du cancer.

[9]  Timothy Cardozo,et al.  The SCF ubiquitin ligase: insights into a molecular machine , 2004, Nature Reviews Molecular Cell Biology.

[10]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[11]  P A Lachenbruch,et al.  Quantitative Changes in the Capillary Bed during Developing, Peak, and Stabilized Cardiac Hypertrophy in the Spontaneously Hypertensive Rat , 1982, Circulation research.

[12]  H. Zingg,et al.  Gene expression profiling of rat uterus at different stages of parturition. , 2003, Endocrinology.

[13]  A. Goldberg,et al.  Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. , 1995, The Biochemical journal.

[14]  Wei Wei,et al.  Expression and activity of C/EBPbeta and delta are upregulated by dexamethasone in skeletal muscle. , 2005, Journal of cellular physiology.

[15]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[16]  K. Chien,et al.  Signaling pathways for cardiac hypertrophy and failure. , 1999, The New England journal of medicine.

[17]  A. Goldberg,et al.  The FOXO3a Transcription Factor Regulates Cardiac Myocyte Size Downstream of AKT Signaling* , 2005, Journal of Biological Chemistry.

[18]  A. Goldberg,et al.  What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? , 2001, Current opinion in clinical nutrition and metabolic care.

[19]  J. Segars,et al.  A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. , 2006, American journal of obstetrics and gynecology.

[20]  A. Goldberg,et al.  Patterns of gene expression in atrophying skeletal muscles: response to food deprivation , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  A. Goldberg,et al.  Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. , 2006, Journal of the American Society of Nephrology : JASN.

[22]  A. Kuroiwa,et al.  Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. , 1996, American heart journal.

[23]  K. Akashi,et al.  Distal elements are critical for human CD34 expression in vivo. , 2002, Blood.

[24]  L. Espey,et al.  Increase in plasminogen activator in the involuting uterus of the postpartum rat. , 1985, Journal of Endocrinology.

[25]  A. Goldberg,et al.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  S. Lye,et al.  Understanding Preterm Labor , 2001, Annals of the New York Academy of Sciences.

[27]  A. Goldberg,et al.  Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. , 1999, The Journal of clinical investigation.

[28]  C. López-Otín,et al.  Collagenase 2 (MMP-8) Expression in Murine Tissue-remodeling Processes , 1998, The Journal of Biological Chemistry.

[29]  J. Woessner Regulation of matrilysin in the rat uterus. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[30]  Wei Wei,et al.  Expression and activity of C/EBPβ and δ are upregulated by dexamethasone in skeletal muscle , 2005 .

[31]  H. Huynh Suppression of uterine insulin-like growth factor binding protein 5 by estrogen is mediated in part by insulin-like growth factor I. , 1998, International journal of oncology.

[32]  S. Houser,et al.  Regression of cellular hypertrophy after left ventricular assist device support. , 1998, Circulation.

[33]  Andrew K Godwin,et al.  Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. , 2003, Molecular cancer therapeutics.